Trial Profile

Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Docetaxel; Fluorouracil; Ligufalimab; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Akeso Biopharma

05 Sep 2024 According to an Akeso media release, the company is going to present data from this study as a late-breaking abstract in the Proffered Paper Session at the ESMO Congress 2024 from September 13th to 17th (CEST).
15 Nov 2023 Planned End Date changed from 30 Aug 2027 to 30 Nov 2027.
15 Nov 2023 Planned primary completion date changed from 30 Aug 2024 to 30 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com